Full-Field OCT vs Histological Analysis for Myositis Diagnosis
Summary
A new observational clinical trial (NCT07552220) registered by NIH on April 27, 2026, will compare full-field optical coherence tomography (OCT) with conventional histological pathology for diagnosing myositis from muscle biopsies. The study aims to establish an OCT reference standard by analyzing control muscle biopsies and comparing muscle inflammation in confirmed myositis cases, evaluating the speed and resolution advantages of the non-invasive imaging technique. This registry entry informs healthcare providers and clinical researchers about an upcoming comparative diagnostic study; it does not itself create compliance obligations.
“This research project compares histological pathology and full-field OCT for the analysis of muscle biopsies from healthy individuals and patients suspected of having myositis.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This is a new clinical trial registration (NCT07552220) for an observational study comparing full-field optical coherence tomography (OCT) with standard histological pathology for myositis diagnosis. The trial will analyze muscle biopsies from healthy individuals and patients suspected of having myositis to establish an OCT reference standard and evaluate the speed and resolution advantages of the imaging technique.
For healthcare providers, clinical investigators, and patients with suspected myositis: this registry entry announces a planned diagnostic study but does not impose any immediate compliance obligations. If the study demonstrates that OCT offers comparable or superior diagnostic capability to histology with faster results, it could inform future diagnostic practices, but the trial itself is informational in nature.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Muscle Imaging Project Using ANatomopathology and Full Field Optical Coherence Tomography
Observational NCT07552220 Kind: OBSERVATIONAL Apr 27, 2026
Abstract
Myositis is an inflammatory disease of the skeletal muscles that can be caused by infections, autoimmune diseases, or medications. Early diagnosis of these conditions is essential for optimal treatment. Anatomic pathology is the conventional method used to analyze muscle lesions, but it requires several weeks to obtain results. Full-field optical coherence tomography (OCT), a non-invasive imaging technique, could offer advantages in terms of speed and resolution for visualizing muscle inflammation.
This research project compares histological pathology and full-field OCT for the analysis of muscle biopsies from healthy individuals and patients suspected of having myositis. The aim of this study is to establish an OCT reference standard by analyzing control muscle biopsies and then comparing muscle inflammation in confirmed cases of myositis. The advantages and limitations of both methods will also be evaluated.
Conditions: Myositis, Health Adult Subjects
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.